| scholarly article | Q13442814 |
| P2093 | author name string | Paul Duffy | |
| Jon Curwen | |||
| Martin Braddock | |||
| Jean-Pierre Valentin | |||
| Eva Lamm Bergström | |||
| Karen Oldman | |||
| Alex Harmer | |||
| Dave Lengel | |||
| Helen Musgrove | |||
| Herb Barthlow | |||
| P2860 | cites work | Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 |
| An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis | Q28294375 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. | Q33382517 | ||
| R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation | Q34562439 | ||
| Targeting Syk as a treatment for allergic and autoimmune disorders | Q35814437 | ||
| Evaluation of hypertension as a marker of bevacizumab efficacy | Q36991546 | ||
| Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics | Q37203741 | ||
| Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 | ||
| VEGF kinase inhibitors: how do they cause hypertension? | Q37480324 | ||
| Bevacizumab-induced hypertension: pathogenesis and management | Q37882684 | ||
| Cardiovascular toxicity of tyrosine kinase inhibitors | Q38096429 | ||
| Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy | Q38101885 | ||
| The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation | Q38925714 | ||
| Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy | Q39981758 | ||
| Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors | Q43245395 | ||
| Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors | Q43430750 | ||
| Navigating the kinome | Q43525185 | ||
| An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents | Q46066669 | ||
| Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab | Q46325595 | ||
| A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist | Q46568872 | ||
| Small sample inference for fixed effects from restricted maximum likelihood. | Q52255259 | ||
| The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. | Q54305524 | ||
| Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud | Q54322103 | ||
| Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. | Q54493173 | ||
| Angiogenesis inhibitors and hypertension: an emerging issue | Q82420687 | ||
| Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma | Q83132843 | ||
| Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors | Q84005593 | ||
| P433 | issue | 5 | |
| P304 | page(s) | e00176 | |
| P577 | publication date | 2015-09-15 | |
| P1433 | published in | Pharmacology Research & Perspectives | Q27725410 |
| P1476 | title | Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents | |
| P478 | volume | 3 |
| Q54144290 | Fostamatinib for persistent/chronic adult immune thrombocytopenia. |
| Q52562217 | Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials. |
| Q96603887 | INSPIRE: A European training network to Foster research and training in cardiovascular safety pharmacology |
| Q92940962 | New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations |
| Q52656283 | Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis. |
Search more.